Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01924143 · ClinicalTrials.gov registry record · Phase 1

TD-9855 Mass Balance Study

A Phase 1 study of ADHD and Fibromyalgia, sponsored by Theravance Biopharma.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target
1
Study location

NCT01924143: Completed Phase 1 study of ADHD and Fibromyalgia, sponsored by Theravance Biopharma.

NCT01924143 is a Phase 1 study of ADHD and Fibromyalgia that has completed, run by Theravance Biopharma. The registered enrollment target is 6 participants, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01924143, a Phase 1 study of ADHD and Fibromyalgia, has completed, sponsored by Theravance Biopharma.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of \[14C\]TD-9855

Primary Outcome

Urinary and fecal recovery of total radioactivity. Whole blood and plasma concentrations of total radioactivity.

Conditions Studied

Interventions

  • DRUG TD-9855

Study Locations (1)

Nebraska

  • - Lincoln

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2013-10
Est. Completion 2013-12
Phase Phase 1
Theravance Biopharma

38 total trials

What the finished NCT01924143 record still lists

NCT01924143 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which TD-9855 is the first listed.

NCT01924143 reports a single indexed study location in Nebraska.

Frequently Asked Questions

What is clinical trial NCT01924143 about?

NCT01924143 is a clinical study titled "TD-9855 Mass Balance Study". The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of \[14C\]TD-9855

What is the current status of trial NCT01924143?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-10. Estimated completion is 2013-12.

What conditions does trial NCT01924143 study?

This clinical trial studies the following conditions: ADHD, Fibromyalgia.

What interventions are being tested in trial NCT01924143?

The interventions under investigation include: TD-9855 (DRUG).

Who is sponsoring clinical trial NCT01924143?

This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01924143 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01924143's enrollment target sits among peer trials

6 75th of 75 the lowest of 75 other ADHD trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other ADHD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01924143, the US trial registry maintained by the National Library of Medicine. NCT01924143 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.